Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis.
Saved in:
| Title: | Efficacy and Safety of Deucravacitinib, a Selective, Allosteric TYK2 Inhibitor, by Baseline DMARD Use in a Phase 2 Psoriatic Arthritis Study: A Post Hoc Analysis. |
|---|---|
| Authors: | Deodhar, Atul1 (AUTHOR) deodhara@ohsu.edu, Nowak, Miroslawa2 (AUTHOR), Ye, June Y.3 (AUTHOR), Lehman, Tom4 (AUTHOR), Banerjee, Subhashis5 (AUTHOR), Mease, Philip J.6 (AUTHOR) |
| Source: | Rheumatology & Therapy. Oct2025, Vol. 12 Issue 5, p873-887. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
